Home » AKORN SIGNS LETTER OF INTENT WITH NATCO PHARMA TO DEVELOP AND SUPPLY TWO ORAL TABLET DRUG PRODUCTS
AKORN SIGNS LETTER OF INTENT WITH NATCO PHARMA TO DEVELOP AND SUPPLY TWO ORAL TABLET DRUG PRODUCTS
Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Natco Pharma Limited (NSE:NATCOPHARM) (MUMBAI:524816), located in Hyderabad, India, to develop and supply two ANDA oral tablet drug products for cancer patients suffering from nausea and vomiting. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Natco.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051219005224&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May